EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Current management of hereditary cancer syndromes in ovarian and endometrial cancer: a Japanese study

Takanori Yokoyama iD, Yasuko Yamamoto, Mika Okazawa-Sakai iD, Natsumi Yamashita, Tomoka Usami, Mihoko Matsumoto, Hiroaki Inui, Masato Nishimura, Tamaki Tanaka, Takashi Ushiwaka, Kazuhiro Takehara iD

Japanese Journal of Clinical Oncology · 2026

DOI: 10.1093/jjco/hyaf176 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Japanese Journal of Clinical Oncology, 2026. Verfasst von Takanori Yokoyama und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecologic Oncology, National Hospital Organization (NHO) Shikoku Cancer Center, Ko-160 Minami-Umemoto cho, Matsuyama City, Ehime 791-…. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Ovarian Neoplasms, Neoplastic Syndromes, Hereditary. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To evaluate the current state of hereditary cancer syndrome management in patients with ovarian and endometrial cancer and to identify the barriers to uptake of genetic testing.

Methods

We conducted a cross-sectional multicenter study at five regional cancer centers in Japan, including 229 patients with ovarian cancer and 454 with endometrial cancer treated between January 2021 and December 2022. We assessed the proportion of patients who received information about hereditary cancer syndromes from gynecologists, underwent genetic counseling with genetic experts, and completed genetic testing; in addition, we explored the barriers to testing uptake.

Results

Among patients with ovarian cancer, 152 (66.4%) received information about hereditary cancer syndromes from their gynecologists, with 61 (26.6%) subsequently receiving genetic counseling and 58 (25.3%) undergoing genetic testing. By contrast, patients with endometrial cancer demonstrated markedly lower rates: only 76 (16.7%) received initial information, 22 (5.3%) accessed genetic counseling, and 13 (2.9%) completed genetic testing. Among patients who received information about hereditary cancer syndromes from their gynecologists, 38% with ovarian cancer and 14% with endometrial cancer underwent genetic testing. Among patients identified as high-risk for hereditary cancer syndromes through tumor profiling, 27.6% (8/29) with ovarian cancer and 70.6% (12/17) with endometrial cancer did not undergo genetic testing. Patient disinterest was the primary barrier to genetic testing among high-risk individuals.

Conclusions

The barriers to uptake of genetic testing arise primarily from inadequate provider communication and patient disinterest in hereditary cancer syndromes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsOvarian NeoplasmsNeoplastic Syndromes, HereditaryHumansFemaleCross-Sectional StudiesJapanMiddle AgedGenetic TestingGenetic CounselingAdultAgedGenetic Predisposition to DiseaseEast Asian People

Stichwörter der Autor:innen

communicationendometrial neoplasmsgenetic counselinggenetic testingovarian neoplasms

Autor:innen und Institutionen

  • Department of Gynecologic Oncology, National Hospital Organization (NHO) Shikoku Cancer Center, Ko-160 Minami-Umemoto cho, Matsuyama City, Ehime 791-0280, Japan.
  • Department of Cancer Genomic Medicine and Hereditary Tumors, NHO Shikoku Cancer Center, Ko-160 Minami-Umemoto cho, Matsuyama City, Ehime 791-0280, Japan.
  • Clinical Research Center, NHO Shikoku Cancer Center, Ko-160 Minami-Umemoto cho, Matsuyama City, Ehime 791-0280, Japan.
  • Department of Obstetrics and Gynecology, Ehime University Graduate School of Medicine, 454 Shitsukawa, Toon City, Ehime 791-0295, Japan.
  • Department of Obstetrics and Gynecology, Tokushima University Graduate School of Medicine, 2-50-1 Kuramoto cho, Tokushima City, Tokushima 770-0042, Japan.
  • Department of Obstetrics and Gynecology, Tokushima Prefectural Central Hospital, 1-10-3 Kuramoto cho, Tokushima City, Tokushima 770-8539, Japan.

ORCID-Profile: Takanori Yokoyama, Mika Okazawa-Sakai, Kazuhiro Takehara

Zitieren

APA

Yokoyama, T., Yamamoto, Y., Okazawa-Sakai, M., Yamashita, N., Usami, T., Matsumoto, M., Inui, H., Nishimura, M., Tanaka, T., Ushiwaka, T., & Takehara, K. (2026). Current management of hereditary cancer syndromes in ovarian and endometrial cancer: a Japanese study. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyaf176

Vancouver

Yokoyama T, Yamamoto Y, Okazawa-Sakai M, Yamashita N, Usami T, Matsumoto M, et al. Current management of hereditary cancer syndromes in ovarian and endometrial cancer: a Japanese study. Japanese Journal of Clinical Oncology. 2026. doi:10.1093/jjco/hyaf176

BibTeX
@article{Yokoyama2026,
  author = {Yokoyama, Takanori and Yamamoto, Yasuko and Okazawa-Sakai, Mika and Yamashita, Natsumi and Usami, Tomoka and Matsumoto, Mihoko and Inui, Hiroaki and Nishimura, Masato and Tanaka, Tamaki and Ushiwaka, Takashi and Takehara, Kazuhiro},
  title = {Current management of hereditary cancer syndromes in ovarian and endometrial cancer: a Japanese study},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1093/jjco/hyaf176}
}
Kostenlos starten →